Thanks; understood, and agreed.@Sherlock It was a serious answer, although somewhat glib.
The afemelanotide technology itself is pretty much bulletproof. The closest competition (MT-7117) is a few years behind, has some potential safety issues that might make it impractical outside of tiny patient populations, and won't even work in most of the other indications that Clinuvel is going for.
The biggest risk, by far, is the inability of management to execute and deliver on the future pipeline. We're in the fortunate position that we don't have to worry about whether our product is safe or will work in future indications. We do, however, have uncertainty about the company's ability to prove it to regulatory agencies and gain approval.
It's not a specific criticism of any employee or board member, but a blanket statement that, relatively speaking, it's the biggest risk to the CUV share price right now. Other relevant factors have been mostly or completely de-risked.
General comment here is that most people in Oz see property as the best means of wealth creation and stock trading as more of a gamble so are few stocks are heavily traded but most are not. There are stats that show compared to our mates in the USA we have lower levels of stock ownership (not counting Superannuation compulsory savings) and lower levels of even having a stock trading account and quality stocks that can exhibit consistent growth are not common on the Australian exchange its often mainly banks or cyclical mining stocks... But this little ripper is showing some good $$$$ growth now just waiting 4 some SP action......For our Aussie friends - are CUV’s occasional anemic trading days, i.e. less than 30k shares for a billion dollar company, an outlier for the ASX or does this happen with other companies as well? Clearly, the registry of shareholders needs to be expanded greatly to get any traction.